ANICCA-Class II : A phase II Trial of nivolumab in strong class II expressing microsatellite stable colorectal cancer patients (MSS CRC)

Billingham, Lucinda (Co-Investigator)
Middleton, Gary (Principal Investigator)

Short title	ANICCA-Class II : A phase II Trial of nivolumab in strong class II expressing microsatellite stable colorectal cancer patients (MSS CRC)
Status	Active
Effective start/end date	1/01/18 → 31/12/27

Funding

Bristol Myers Squibb Pharmaceuticals

1 Article

Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1
Middleton, G., Gaskell, C., Savage, J., Bridgewater, J., Ross, P., Saunders, M., Palmer, D., Plummer, R., Clive, S., Coyle, V., Thomas, A., Cunningham, D., Taniere, P. & Billingham, L., 17 Dec 2025, In: Journal for ImmunoTherapy of Cancer. 13, 12, 13 p., e012749.
Research output: Contribution to journal › Article › peer-review

Open Access
File
4 Downloads (Pure)